

158th Session of WHO Executive Board Meeting

2nd to 7th February 2026, Geneva



**Ministry of Health & Family Welfare
Government of India**

Intervention by India

Agenda Item 12: Substandard and falsified medical products

(Word Count: 140)

Thank you chair,

India endorses the proposed streamlined workplan for 2026–2027, particularly the prioritization of activities related to detection technologies, risk communication, unregulated distribution channels, and strengthening oversight of high-risk excipient supply chains.

India has implemented several best practices through the Central Drugs Standard Control Organization (CDSCO) and State Drug Regulatory Authorities to prevent, detect, and respond to Substandard and falsified medical products. These include the adoption of risk-based inspections and enhanced market surveillance, implementation of a national drug track-and-trace system for exported pharmaceutical products, with progressive strengthening of domestic traceability.

Our extensive network of drug testing laboratories, supported by risk-based sampling and digital platforms, further reinforces vigilance, licensing and regulatory communication.

Chair

India emphasizes retaining the Member State–driven character of the Member State Mechanism, focusing on practical and implementable outputs, and prioritizing regulatory capacity strengthening.

Thank you!